HC Wainwright Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $80.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 422.53% from the company’s current price. […]
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $80.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 422.53% from the company’s current price. […]
